The global life sciences industry has been on the rise, growing more rapidly than ever over the past decade. Its pace increased significantly during the pandemic throughout 2020 and 2021 with demand surging and access to capital continuing to expand.

As the global community races to develop new vaccines, ramp up production and distribution to combat coronavirus, India is also strengthening its position in the life sciences industry. Currently, India is hailed as the largest provider of generics globally and is referred to as the pharmacy of the world.

Favourable government policies, large skilled workforce, and cost efficiencies, among many other factors, are attracting venture capital funding into the life sciences segment. India is gaining momentum to develop a robust life sciences R&D hub that will likely present a lucrative opportunity for private equity investors.

Savills India brings to you its latest report On a Booster Dose: Life Sciences Real Estate where we estimate the growth of the life sciences R&D segment in India along with the potential private equity institutional investment opportunities based on a range of growth rate estimates.